Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 3
2009 1
2012 4
2013 6
2014 6
2015 5
2016 2
2017 6
2018 6
2019 1
2021 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Children's Oncology Group's 2023 blueprint for research.
Hawkins DS, Gore L. Hawkins DS, et al. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30569. doi: 10.1002/pbc.30569. Epub 2023 Jul 11. Pediatr Blood Cancer. 2023. PMID: 37433635 No abstract available.
Durable remission for four pediatric patients with high-risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation: A report from the Children's Oncology Group.
Buhtoiarov IN, Mba NI, Santos CDL, McCarten KM, Metzger ML, Pei Q, Bush R, Baker K, Kelly KM, Cole PD. Buhtoiarov IN, et al. Pediatr Blood Cancer. 2022 Jun;69(6):e29649. doi: 10.1002/pbc.29649. Epub 2022 Mar 26. Pediatr Blood Cancer. 2022. PMID: 35338689 Free PMC article.
A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).
Mossé YP, Fox E, Teachey DT, Reid JM, Safgren SL, Carol H, Lock RB, Houghton PJ, Smith MA, Hall D, Barkauskas DA, Krailo M, Voss SD, Berg SL, Blaney SM, Weigel BJ. Mossé YP, et al. Clin Cancer Res. 2019 Jun 1;25(11):3229-3238. doi: 10.1158/1078-0432.CCR-18-2675. Epub 2019 Feb 18. Clin Cancer Res. 2019. PMID: 30777875 Free PMC article. Clinical Trial.
A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315).
Geller JI, Fox E, Turpin BK, Goldstein SL, Liu X, Minard CG, Kudgus RA, Reid JM, Berg SL, Weigel BJ. Geller JI, et al. Cancer. 2018 Dec 1;124(23):4548-4555. doi: 10.1002/cncr.31725. Epub 2018 Nov 5. Cancer. 2018. PMID: 30394521 Free PMC article. Clinical Trial.
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.
Cole PD, McCarten KM, Pei Q, Spira M, Metzger ML, Drachtman RA, Horton TM, Bush R, Blaney SM, Weigel BJ, Kelly KM. Cole PD, et al. Lancet Oncol. 2018 Sep;19(9):1229-1238. doi: 10.1016/S1470-2045(18)30426-1. Epub 2018 Aug 16. Lancet Oncol. 2018. PMID: 30122620 Free PMC article. Clinical Trial.
A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Schafer ES, Rau RE, Berg S, Liu X, Minard CG, D'Adamo D, Scott R, Reyderman L, Martinez G, Devarajan S, Reid JM, Fox E, Weigel BJ, Blaney SM. Schafer ES, et al. Pediatr Blood Cancer. 2018 Aug;65(8):e27066. doi: 10.1002/pbc.27066. Epub 2018 May 2. Pediatr Blood Cancer. 2018. PMID: 29719113 Free PMC article. Clinical Trial.
38 results